Anthera Pharmaceuticals, Inc.
ANTHOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$26179
P/E Ratio—
52W High$0.001
52W Low$0.0001
Anthera Pharmaceuticals, Inc. (ANTH) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ANTH · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2018Report Date: May 15, 2018EPS Actual
-$0.42
Est. -$0.60 · +30.0%
Revenue
—
Fiscal Period
Q2 FY2018
FY ends December
Report Date
May 15, 2018
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
ANTH reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.02
Rev. $0.33B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.02
Rev. Est.$0.33B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2018 | Sep 17, 2018 | — | — | — | — | — | — |
| ▲ Q2 FY2018 | May 15, 2018 | -$0.60 | -$0.42 | +30.0% | — | — | — |
| ▼ Q1 FY2018 | Mar 5, 2018 | -$0.71 | -$0.73 | -2.8% | — | — | — |
| ▲ Q4 FY2017 | Nov 6, 2017 | -$0.90 | -$0.58 | +35.6% | — | — | — |
| ▲ Q3 FY2017 | Aug 9, 2017 | -$1.08 | -$0.86 | +20.4% | — | — | — |
| ▼ Q2 FY2017 | May 10, 2017 | -$1.39 | -$2.03 | -46.0% | — | — | — |
| ▲ Q1 FY2017 | Feb 27, 2017 | -$3.28 | -$2.88 | +12.2% | — | — | — |
| ▼ Q4 FY2016 | Nov 4, 2016 | -$2.80 | -$4.88 | -74.3% | — | — | — |
Q3 FY2018
Sep 17, 2018
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2018
May 15, 2018Beat
EPS Actual
-$0.42
EPS Est.
-$0.60
EPS Surpr.
+30.0%
Revenue
—
Q1 FY2018
Mar 5, 2018Miss
EPS Actual
-$0.73
EPS Est.
-$0.71
EPS Surpr.
-2.8%
Revenue
—
Q4 FY2017
Nov 6, 2017Beat
EPS Actual
-$0.58
EPS Est.
-$0.90
EPS Surpr.
+35.6%
Revenue
—
Q3 FY2017
Aug 9, 2017Beat
EPS Actual
-$0.86
EPS Est.
-$1.08
EPS Surpr.
+20.4%
Revenue
—
Q2 FY2017
May 10, 2017Miss
EPS Actual
-$2.03
EPS Est.
-$1.39
EPS Surpr.
-46.0%
Revenue
—
Q1 FY2017
Feb 27, 2017Beat
EPS Actual
-$2.88
EPS Est.
-$3.28
EPS Surpr.
+12.2%
Revenue
—
Q4 FY2016
Nov 4, 2016Miss
EPS Actual
-$4.88
EPS Est.
-$2.80
EPS Surpr.
-74.3%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2019 | $-0.03 | $-0.03 | $-0.03 | 11 |
| Q3 FY2019 | $-0.03 | $-0.03 | $-0.03 | 7 |
| Q2 FY2019 | $-0.03 | $-0.03 | $-0.03 | 12 |
| Q1 FY2019 | $-0.02 | $-0.02 | $-0.02 | 7 |
| Q3 FY2018 | $0.00 | $0.00 | $0.00 | 6 |
| Q2 FY2018 | $0.00 | $0.00 | $0.00 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2019 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2019 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2019 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2019 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2018 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2018 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2018 | May 15, 2018 | +30.0% | $0.32 | $0.31 | -1.01% |
| ▼ Q1 FY2018 | Mar 5, 2018 | -2.8% | $2.34 | $2.52 | +7.69% |
| ▲ Q4 FY2017 | Nov 6, 2017 | +35.6% | $1.78 | $1.63 | -8.43% |
| ▲ Q3 FY2017 | Aug 9, 2017 | +20.4% | $1.32 | $1.46 | +10.61% |
| ▼ Q2 FY2017 | May 10, 2017 | -46.0% | $2.29 | $2.26 | -1.31% |
| ▲ Q1 FY2017 | Feb 27, 2017 | +12.2% | $5.55 | $5.67 | +2.16% |
| ▼ Q4 FY2016 | Nov 4, 2016 | -74.3% | $16.88 | $18.80 | +11.37% |
| ▼ Q3 FY2016 | Aug 9, 2016 | -12.9% | $24.72 | $24.64 | -0.32% |
Q2 FY2018-1.01%
Report Date
May 15, 2018
EPS Beat/Miss
+30.0%
Price Before
$0.32
Price After
$0.31
Q1 FY2018+7.69%
Report Date
Mar 5, 2018
EPS Beat/Miss
-2.8%
Price Before
$2.34
Price After
$2.52
Q4 FY2017-8.43%
Report Date
Nov 6, 2017
EPS Beat/Miss
+35.6%
Price Before
$1.78
Price After
$1.63
Q3 FY2017+10.61%
Report Date
Aug 9, 2017
EPS Beat/Miss
+20.4%
Price Before
$1.32
Price After
$1.46
Q2 FY2017-1.31%
Report Date
May 10, 2017
EPS Beat/Miss
-46.0%
Price Before
$2.29
Price After
$2.26
Q1 FY2017+2.16%
Report Date
Feb 27, 2017
EPS Beat/Miss
+12.2%
Price Before
$5.55
Price After
$5.67
Q4 FY2016+11.37%
Report Date
Nov 4, 2016
EPS Beat/Miss
-74.3%
Price Before
$16.88
Price After
$18.80
Q3 FY2016-0.32%
Report Date
Aug 9, 2016
EPS Beat/Miss
-12.9%
Price Before
$24.72
Price After
$24.64
Avg Beat Reaction+0.83%
Avg Miss Reaction+4.36%
Beat Rate4 / 8 quarters
Largest Move+11.37% (Q4 FY2016)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ANTH ends December
Anthera Pharmaceuticals, Inc. (ANTH) most recently reported earnings on May 15, 2018 for Q2 FY2018, posting EPS of $-0.42 — beating the analyst consensus of $-0.60 by +30.0%. The next ANTH earnings date is expected around September 1, 2026.
Each quarter, investors track ANTH earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ANTH revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ANTH's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ANTH earnings · 5 questionsAnthera Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. ANTH typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ANTH historically reports after market close (AMC).
ANTH earnings datewhen is ANTH earningsANTH next earnings datewhen does ANTH report earningsANTH earnings calendar
▸ Source: FMP · Anthera Pharmaceuticals, Inc. SEC filings · US GAAP · Anthera Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026